Krystal Biotech, Inc. (KRYS) Stock
KRYS Key Statistics
About Krystal Biotech, Inc.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
CEO: Krish S. Krishnan. Company website
KRYS — Frequently Asked Questions
What is the KRYS stock price today?
Krystal Biotech, Inc. (KRYS) trades at $308.81, up 0.75% on the day, as of Nov 12, 2026 10:46 UTC.
What is Krystal Biotech, Inc.'s market cap?
Krystal Biotech, Inc. has a market capitalisation of $9.15B, calculated from the live KRYS share price and shares outstanding.
What is the P/E ratio of KRYS?
KRYS trades at a trailing P/E of 41.94, from earnings per share of $7.36 over the last twelve months.
How much revenue does Krystal Biotech, Inc. make?
Krystal Biotech, Inc. generated revenue of $470.03M over the trailing twelve months, which puts the stock at 19.47 times sales.
What is the 52-week range for KRYS?
KRYS has traded between $192.52 and $382.54 over the past 52 weeks, and the last price is 19.3% below that high.
Is Krystal Biotech, Inc. profitable?
Yes. Krystal Biotech, Inc. keeps 47.91% of revenue as net income over the trailing twelve months.
What is the analyst price target for KRYS?
Wall Street analysts rate KRYS Buy, with an average price target of $419.00, 35.7% above the current price.
What sector is Krystal Biotech, Inc. in?
Krystal Biotech, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Krystal Biotech, Inc.?
Krish S. Krishnan is the chief executive of Krystal Biotech, Inc., which employs 295 people.
Where can I track KRYS in real time?
QFI Terminal shows KRYS with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See KRYS live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open KRYS in Terminal See plans